Psychiatric Manifestations of Cushing’s Syndrome

  • Peter T. Loosen

Abstract

The constellation of clinical signs and symptoms that we now call “Cushing’s syndrome” was first described by Cushing in 1932. Cushing’s syndrome results from chronic exposure to excessive concentrations of glucocorticoids. The physical features of Cushing’s syndrome include weight gain, central obesity (i.e., accumulation of adipose tissue in the facial, nuchal, truncal and girdle areas), facial plethora, hirsutism, cutaneous striae, muscle wasting, weakness, and osteoporosis. Other common manifestations of hypercortisolemia include hypertension, glucose intolerance or diabetes mellitus, impotence and testicular atrophy, amenorrhea, mild erythrocytosis, lymphopenia, eosinopenia and frequent fungal infections. Cushing’s syndrome can be divided into two major categories, each of which has two major causes. ACTH-dependent Cushing’s syndrome can be caused by excessive ACTH secretion by a pituitary microadenoma (referred to as “Cushing’s disease”) or by ACTH secretion by a non-pituitary tumor (“ectopic ACTH syndrome”), usually a small cell carcinoma of the lung or a bronchial, thymic or pancreatic carcinoid tumor, which together account for 75% of all cases. ACTH-independent Cushing’s syndrome is caused by adrenocortical tumors that secrete cortisol autonomously or by administration of pharmacologic doses of synthetic glucocorticoids.

Keywords

Osteoporosis Adenoma Dementia Schizophrenia Dexamethasone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cushing H. The basophil adenomas of the pituitary body and their clinical manifestation (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137–195.Google Scholar
  2. 2.
    Orth DN, Kovacs WJ, deBold CR. The adrenal cortex. In: Wilson JD, Foster DW, editors. Williams Textbook of Endocrinology. Philadelphia: W.B. Saunders, 1992: 489–619.Google Scholar
  3. 3.
    Yanovski JA, Cutler GBJ. Glucocorticoid action and the clinical features of Cushing’s syndrome. Endocrinol Metab Clin North Am 1994; 23(3):487–509.PubMedGoogle Scholar
  4. 4.
    Krieger DT. Physiopathology of Cushing’s disease. Endocr Rev 1983; 4:22–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Orth DN. Medical progress: Cushing’s syndrome. N Engl J Med 1995; 332:791–803.PubMedCrossRefGoogle Scholar
  6. 6.
    Gold PW, Chrousos G, Kellner C et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry 1984; 141:619–627.PubMedGoogle Scholar
  7. 7.
    Nathan KI, Musselman DL, Nemeroff CB. Biology of mood disorders. In: Schatzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology. Washington: American Psychiatric Press, 1995.Google Scholar
  8. 8.
    Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry 1985; 142:911–916.PubMedGoogle Scholar
  9. 9.
    Hudson JI, Hudson MS, Griffing GT, Melby JC, Pope HGJ. Phenomenology and family history of affective disorder in Cushing’s disease. Am J Psychiatry 1987; 144:951–953.PubMedGoogle Scholar
  10. 10.
    Sonino N, Fava GA, Belluardo P, Girelli ME, Boscaro M. Course of depression in Cushing’s syndrome: response to treatment and comparison with Graves’ disease. Hormone Research 1993; 39(5–6):202–206.PubMedCrossRefGoogle Scholar
  11. 11.
    Dom LD, Burgess ES, Dubbert B et al. Psychopathology in patients with endogenous Cushing’s syndrome: ‘Atypical’ or melancholic features. Clinical Endocrinology 1995; 43(4):433–442.CrossRefGoogle Scholar
  12. 12.
    Loosen PT, Chambliss B, deBold CR, Shelton R, Orth DN. Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiat 1992; 25(4): 192–198.CrossRefGoogle Scholar
  13. 13.
    Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82(3):912–919.PubMedCrossRefGoogle Scholar
  14. 14.
    Sonino N, Fava GA, Raffi AR, Boscaro M, Fallo F. Clinical correlates of major depression in Cushing’s disease. Psychopathology 1998; 31(6):302–306.PubMedCrossRefGoogle Scholar
  15. 15.
    Kelly WF. Psychiatric aspects of Cushing’s syndrome. QJM 1996; 89(7):543–551.PubMedCrossRefGoogle Scholar
  16. 16.
    American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders (DSM-IV). Fourth ed. Washington: American Psychiatric Association, 1994.Google Scholar
  17. 17.
    Boyd JH, Weissman MM. Epidemiology. In: Paykel ES, editor. Handbook of Affective Disorders. New York: Guilford Press, 1982: 109–125.Google Scholar
  18. 18.
    Pearson Murphy BE. Steroids and depression. J Steroid Biochem Molec Biol 1991; 38:537–559.CrossRefGoogle Scholar
  19. 19.
    Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 1985; 42:1193–1204.PubMedCrossRefGoogle Scholar
  20. 20.
    Miller KB, Nelson JC. Does the dexamethasone suppression test relate to subtypes, factors, symptoms, or severity? Arch Gen Psychiatry 1987; 44:769–774.PubMedCrossRefGoogle Scholar
  21. 21.
    Thakore JH, Dinan TG. Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995; 37:364–368.PubMedCrossRefGoogle Scholar
  22. 22.
    Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H. Ketokonazole administration in hypercortisolemic depression. Am J Psychiatry 1993; 150:810–812.PubMedGoogle Scholar
  23. 23.
    Pearson Murphy BE, Ghadirian AM, Filipini D, Dhar V. Endocrine responses to antiglucocorticoid strategies in refractory depression. Biol Psychiatry 1994; 35:618.CrossRefGoogle Scholar
  24. 24.
    Ghadirian AM, Engelsman F, Dhar V et al. Psychotropic effects of steroid synthesis inhibitors in refractory depression. Biol Psychiatry 1994; 35:618.CrossRefGoogle Scholar
  25. 25.
    Wolkowitz OM, Reus VI, Manfredi F et al. Antiglucocorticoid medication effects on specific depressive symptoms. Biol Psychiatry 1994; 35:678–679.CrossRefGoogle Scholar
  26. 26.
    Nemeroff CB. The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiat 1994; 21:76–82.CrossRefGoogle Scholar
  27. 27.
    Nemeroff CB, Widerlov E, Bissette G et al. Elevated concentrations of CSF corticotropinreleasing factor-like immunoreactivity in depressed patients. Science 1984; 226:1342–1344.PubMedCrossRefGoogle Scholar
  28. 28.
    Geracioti TD, Orth DN, Ekhator NN, Blumenkopf B, Loosen PT. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed subjects. J Clin Endocrinol Metab 1992; 74: 1325–1330.PubMedCrossRefGoogle Scholar
  29. 29.
    Kling MA, Roy A, Doran AR et al. Cerebrospinal fluid immunoreactive corticotropinreleasing hormone and adrenocorticotropin secretion in Cushing’s disease and major depression: potential clinical implications [see comments]. J Clin Endocrinol & Metab 1991; 72(2):260–271.CrossRefGoogle Scholar
  30. 30.
    Stewart MA, Drake F, Winokur G. Depression among medically ill patients. Dis Nerv Syst 1965; 26:479–485.PubMedGoogle Scholar
  31. 31.
    Schwab JJ, Bialow M, Brown JM, Holzer CE. Diagnosing depression in medical inpatients. Ann Intern Med 1967; 67:695–707.PubMedGoogle Scholar
  32. 32.
    Moffic HS, Paykel ES. Depression in medical in-patients. Brit J Psychiatry 1975; 126:346–353.CrossRefGoogle Scholar
  33. 33.
    Abdel-Nasser AM, Abd EI-Azim S, Taal E, El Badawy SA, Rasker JJ, Valkenburg HA. Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 1998; 37(4):391–397.PubMedCrossRefGoogle Scholar
  34. 34.
    Starkman MN, Schteingart DE. Neuropsychiatric manisfestations of patients with Cushing’s syndrome: Relationship to cortisol and adrenocorticotropin hormone levels. Arch Intern Med 1981; 141:215–219.PubMedCrossRefGoogle Scholar
  35. 35.
    Grigoriadis DE, Pearsall D, deSouza EB. Effects of chronic antidepressant and benzodiazepine treatment on corticotropin-releasing factor receptors in rat brain and pituitary. Neuropsychopharm 1988; 2:53–60.CrossRefGoogle Scholar
  36. 36.
    Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing’s syndrome: Relationship to hormone levels. Psychosom Med 1981; 43:3–18.PubMedGoogle Scholar
  37. 37.
    Cohen SI. Cushing’s syndrome: A psychiatric study of 29 patients. Brit J Psychiatry 1980; 136:120–124.CrossRefGoogle Scholar
  38. 38.
    Kelly WF, Checkley SA, Bender DA, Mashiter K. Cushing’s syndrome and depression—a prospective study of 26 patients. Brit J Psychiatry 1983; 142:16–19.CrossRefGoogle Scholar
  39. 39.
    Jeffcoate WJ, Silverstone J, Edwards C, Besser G. Psychiatric man ifestation of Cushing’s syndrome: response to lowering of plasma cortisol. Qtrly J Med 1979; 48:465–472.Google Scholar
  40. 40.
    Kelly WF, Checkley SA, Bender DA. Cushing’s syndrome, tryptophan and depression. Brit J Psychiatry 1980; 136:125–132.CrossRefGoogle Scholar
  41. 41.
    Sonino N, Fava GA. Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 1998; 67(3):140–146.PubMedCrossRefGoogle Scholar
  42. 42.
    Voigt KH, Bossert S, Bretschneider S, Bliestle A, Fehm HL. Disturbed cortisol secretion in man: contrasting Cushing’s disease and endogenous depression. Psychiatry Res 1985; 15(4):341–350.PubMedCrossRefGoogle Scholar
  43. 43.
    Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55(7):580–592.PubMedCrossRefGoogle Scholar
  44. 44.
    Cushing H. Psychic disturbances associated with disorders of the ductless glands. Am J of Insanity 1913; 69:965–990.Google Scholar
  45. 45.
    Gifford S, Gunderson JG. Cushing’s disease as a psychosomatic disorder: A selective review of the clinical and experimental literature and a report of ten cases. Persp Biol Med 1970; 13:169–221.Google Scholar
  46. 46.
    Sonino N, Fava GA, Grandi S, Mantero F, Boscaro M. Stressful life events in the pathogenesis of Cushing’s disease. Clin Endocrinol 1988; 29:617–623.CrossRefGoogle Scholar
  47. 47.
    Isojarvi JI, Myllyla VV, Pakarinen AJ. Effects of carbamazepine on pituitary responsiveness to luteinizing hormone-releasing hormone, thyrotropin-releasing hormone, and metoclopramide in epileptic patients. Epilepsia 1989; 30(1):50–56.PubMedCrossRefGoogle Scholar
  48. 48.
    Reus VI. Neuropsychiatric disturbance in endocrine disease. In: Nemeroff CB, Loosen PT, editors. Handbook of Clinical Psychoneuroendocrinology. New York: Guilford Press, 1988: 71–84.Google Scholar
  49. 49.
    Mazet P, Simon D, Luton JP, Bricaire H. [Psychic symptoms and personality of 50 patients with Cushing’s syndrome (author’s transl)]. Nouv Presse Med 1981; 10(31):2565–2570.PubMedGoogle Scholar
  50. 50.
    McEwen BS, Angulo J, Cameron H et al. Paradoxical effects ofadrenal steroids on the brain: protection versus degeneration. Biol Psychiatry 1992; 31:177–199.PubMedCrossRefGoogle Scholar
  51. 51.
    Kellner C, Rubinow D, Gold P, Post R. Relationship of cortisol hypersecretion and brain CT scan alterations in depressed patients. Psychiat Res 1983; 8:191–197.CrossRefGoogle Scholar
  52. 52.
    Schlegel S, von Bardeleben U, Wiedemann K, Frommberger U, Holsboer F. Computerized brain tomography measures compared with spontaneous and suppressed cortisol levels in major depression. Psychoneuroendocr 1989; 14:209–216.CrossRefGoogle Scholar
  53. 53.
    Bentson JR, Reza M, Winter J, Wilson G. Steroids and apparent cerebral atrophy on computed tomography scans. J Comput Assist Tomogr 1978; 2:16–23.PubMedCrossRefGoogle Scholar
  54. 54.
    Okuno T, Ito M, Knoishi Y, Yoshioka MK, Nakano Y. Cerebral atrophy following ACTH therapy. J Comput Assist Tomogr 1980; 4:20–23.PubMedCrossRefGoogle Scholar
  55. 55.
    Heinz ER, Martinez J, Haenggeli A. Reversibility of cerebral atrophy in anorexia nervosa. J Comput Assist Tomogr 1977; 1:415–418.PubMedCrossRefGoogle Scholar
  56. 56.
    Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region:enduring memory impairment following a bilateral lesion limited to field CAl of the hippocampus. J Neurosci 1986; 6:2950–2967.PubMedGoogle Scholar
  57. 57.
    Squire LR, Shimamura AP, Amaral DG. Memory and the hippocampus. In: Byrne J, Berry W, editors. Neural Modes of Plasticity. New York: Academic Press, 1989: 208–239.Google Scholar
  58. 58.
    Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. I Neurosci 1990; 10:2897–2902.Google Scholar
  59. 59.
    Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 1992; 32(9):756–765.PubMedCrossRefGoogle Scholar
  60. 60.
    Axelson DA, Doraiswamy PM, McDonald WM et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993; 47: 163–173.PubMedCrossRefGoogle Scholar
  61. 61.
    Krishnan KR, Doraiswamy PM, Figiel GS et al. Hippocampal abnormalities in depression. J Neuropsych & Clin Neurosciences 1991; 3(4):387–391.Google Scholar
  62. 62.
    Bremner JD, Randall P, Scott TM et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 1995; 152(7):973–981.PubMedGoogle Scholar
  63. 63.
    Ling MHM, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Arch Gen Psychiatry 1981; 38:471–477.PubMedCrossRefGoogle Scholar
  64. 64.
    The Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972; 13:695–698.Google Scholar
  65. 65.
    Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. J Affect Dis 1994; 5:319–332.CrossRefGoogle Scholar
  66. 66.
    Goolker P, Schein J. Psychic effects of ACTH and cortisone. Psychosom Med 1953; 15:589–613.PubMedGoogle Scholar
  67. 67.
    Wolkowitz OM, Rubinow D, Doran AR et al. Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry 1990; 47(10):963–968.PubMedCrossRefGoogle Scholar
  68. 68.
    Price R. A Whole New Life. An Illness and a Healing. New York: Macmillan, 1994.Google Scholar
  69. 69.
    Varney NR, Alexander B, McIndoe JH. Reversible steroid dementia in patients without steroid psychoses. Am J Psychiatry 1984; 141:369–372.PubMedGoogle Scholar
  70. 70.
    Hall RCW, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis 1979; 167:229–236.PubMedCrossRefGoogle Scholar
  71. 71.
    Reckart MD, Eisendrath SJ. Exogenous corticosteroid effects on mood and cognition: case presentations. Interntl J of Psychosomatics 1990; 37(1–4):57–61.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Peter T. Loosen
    • 1
  1. 1.Department of PsychiatryVanderbilt School of MedicineNashvilleUSA

Personalised recommendations